Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04254978
Other study ID # IMG-7289-CTP-201
Secondary ID MK-3543-0032019-
Status Completed
Phase Phase 2
First received
Last updated
Start date September 8, 2020
Est. completion date March 23, 2023

Study information

Verified date March 2024
Source Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA)
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a Phase 2b open label study of an orally administered LSD1 inhibitor, Bomedemstat (MK-3543, formerly called IMG-7289), in patients with essential thrombocythemia. This study investigates the following: - The safety and tolerability of Bomedemstat - The pharmacodynamic effect of Bomedemstat


Description:

This is a Phase 2 multi-center, open-label study evaluating the safety, efficacy and pharmacodynamics of Bomedemstat administered orally once daily in patients with essential thrombocythemia (ET). Patients will be dosed with Bomedemstat for 169 consecutive days in the Initial Treatment Period (ITP). Qualifying patients may continue to receive Bomedemstat in the Additional Treatment Period (ATP). Safety will be evaluated by clinical assessments of safety parameters i.e., safety laboratory testing, adverse event reporting, physical examination and vital sign assessments. Pharmacodynamics will be evaluated by hematology assessment, patient reported symptom burden, change in spleen size by palpation and other measures. To ensure safety, a Safety Advisory Board will perform periodic reviews of safety parameters and pharmacodynamic markers.


Recruitment information / eligibility

Status Completed
Enrollment 73
Est. completion date March 23, 2023
Est. primary completion date March 23, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Diagnosis of Essential Thrombocythemia per World Health Organization (WHO) diagnostic criteria for myeloproliferative neoplasms. - Requires treatment in order to lower platelet count based on patient age over 60 or history of thrombosis. - Have failed at least one standard therapy - Must have discontinued ET therapy at least 1 week (4 weeks for interferon) prior to study drug initiation. Exclusion Criteria: - Has undergone major surgery =4 weeks prior to starting study drug or has not recovered from side effects of such surgery. - Unresolved treatment related toxicities from prior therapies (unless resolved to = Grade 1). - Uncontrolled active infection. - Current use of prohibited medications - Known HIV infection or active Hepatitis B or Hepatitis C virus infection - Other hematologic/biochemistry requirements, as per protocol - Use of investigational agent within last 14 days - Pregnant or lactating females

Study Design


Intervention

Drug:
Bomedemstat
Oral administration

Locations

Country Name City State
Australia Royal Adelaide Hospital Adelaide South Australia
Australia Local Institution Camperdown New South Wales
Australia Local Institution Clayton Victoria
Australia Local Institution Herston Brisbane
Australia Local Institution Southport Queensland
Australia Local Institution St Leonards New South Wales
Germany Department of Hematology and Stem Cell Transplantation, West German Cancer Center (WTZ) Essen
Germany Local Institution Jena
Hong Kong Local Institution Hong Kong
Italy Local Institution Alessandria
Italy Local Institution Bologna
Italy CRIMM; Centro Ricerca e Innovazione delle Malattia Mieloproliferative, Azienda ospedaliera Universitaria Careggi Florence
Italy Local Institution Varese
New Zealand Local Institution Auckland
New Zealand Middlemore Hospital Auckland
United Kingdom Guys and St Thomas Hospital London
United Kingdom Local Institution London
United Kingdom Local Institution London
United Kingdom Local Institution Oxford
United States Local Institution Ann Arbor Michigan
United States Cleveland Clinic Cleveland Ohio
United States Local Institution Durham North Carolina
United States Local Institution Jacksonville Florida
United States Local Institution New York New York
United States Local Institution Pittsburgh Pennsylvania
United States Local Institution Seattle Washington

Sponsors (1)

Lead Sponsor Collaborator
Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA)

Countries where clinical trial is conducted

United States,  Australia,  Germany,  Hong Kong,  Italy,  New Zealand,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of Participants Who Experienced an Adverse Event (AE) An AE is any undesirable physical, psychological or behavioral effect experienced by a participant during the study, in conjunction with the use of the drug or biologic, whether or not product related. This includes any untoward signs or symptoms experienced by the participant from the time of first dose with study treatment until completion of the study. The number of participants who experienced an AE is reported. Up to approximately 30 months
Primary Number of Participants Who Discontinued Study Treatment Due to an AE An AE is any undesirable physical, psychological or behavioral effect experienced by a patient during participation in the study, in conjunction with the use of the drug or biologic, whether or not product-related. This includes any untoward signs or symptoms experienced by the patient from the time of first dose with study treatment until completion of the study. The number of participants who discontinued study treatment due to an AE is reported. Up to approximately 28 months
Primary Percentage of Participants With Platelet Count =400 k/µL at Day 169 Blood samples were collected at pre-specified timepoints to determine platelet counts. The percentage of participants who achieved reduction in platelet count to =400k/µL in the absence of new thrombolytic events is reported. Up to day 169
See also
  Status Clinical Trial Phase
Recruiting NCT05482971 - A Single-arm, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of P1101 in Adults With ET Phase 2
Active, not recruiting NCT03289910 - Topotecan Hydrochloride and Carboplatin With or Without Veliparib in Treating Advanced Myeloproliferative Disorders and Acute Myeloid Leukemia or Chronic Myelomonocytic Leukemia Phase 2
Recruiting NCT02897297 - Myeloproliferative Neoplastic Diseases Observatory From Brest
Completed NCT00666549 - Research Tissue Bank
Completed NCT00052520 - Biological Therapy in Treating Patients With Advanced Myelodysplastic Syndrome, Acute or Chronic Myeloid Leukemia, or Acute Lymphoblastic Leukemia Who Are Undergoing Stem Cell Transplantation Phase 1/Phase 2
Completed NCT01192347 - French Observational Xagrid (FOX) Study In Adult Patients With Essential Thrombocythemia
Completed NCT01588015 - Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant Phase 1
Recruiting NCT04942080 - Interest of CALR Allele Burden in Diagnosis and Follow-up of Patients With CALR Mutated Myeloproliferative Syndromes (CALRSUIVI) N/A
Recruiting NCT05031897 - Reduced-Intensity Conditioning for the Prevention of Treatment-Related Mortality in Patients Who Undergo a Hematopoietic Stem Cell Transplant Phase 2
Active, not recruiting NCT04262141 - IMG-7289 in Patients With Essential Thrombocythemia (ET) or Polycythemia Vera (PV) Phase 2
Completed NCT03907436 - The NUTRIENT Trial (NUTRitional Intervention Among myEloproliferative Neoplasms): Feasibility Phase N/A
Active, not recruiting NCT00588991 - Veliparib and Topotecan With or Without Carboplatin in Treating Patients With Relapsed or Refractory Acute Leukemia, High-Risk Myelodysplasia, or Aggressive Myeloproliferative Disorders Phase 1
Completed NCT00112593 - Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer N/A
Completed NCT01787552 - A Phase Ib/II Dose-finding Study to Assess the Safety and Efficacy of LDE225 + INC424 in Patients With MF Phase 1/Phase 2
Recruiting NCT03116542 - 18F-FLT (PET/CT) in Prefibrotic/Early Primary Myelofibrosis and Essential Thrombocythemia N/A
Recruiting NCT06361641 - Functional and Phenotypic Characterization of Monocytes in Myeloproliferative Syndromes N/A
Recruiting NCT06378437 - A Study of GLB-001 in Patients With Myeloid Malignancies Phase 1
Recruiting NCT05882773 - Asian Myeloproliferative Neoplasm (MPN) Registry
Completed NCT02129101 - Azacitidine and Sonidegib or Decitabine in Treating Patients With Myeloid Malignancies Phase 1
Completed NCT00357305 - Vorinostat, Cytarabine, and Etoposide in Treating Patients With Relapsed and/or Refractory Acute Leukemia or Myelodysplastic Syndromes or Myeloproliferative Disorders Phase 1